{"id":154,"date":"2024-05-17T10:00:00","date_gmt":"2024-05-17T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=154"},"modified":"2025-09-02T13:00:44","modified_gmt":"2025-09-02T13:00:44","slug":"china-newco-2024-hengrui-and-hercules-cm-newco-enters-a-license-on-4-glp-1-ptograms","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/154.html","title":{"rendered":"[China NewCo 2024] Hengrui  and Hercules CM NewCo enters a license on 4 GLP-1 Programs"},"content":{"rendered":"\n<p>Announced Date: 2024-08-29 (May 29, 2024)<\/p>\n\n\n\n<p>Key Asset: Four GLP-1 Programs, HRS9531 (KAI-9531)\u3001HRS-7535 (KAI-7535)\u3001HRS-4729 (KAI-4729)<\/p>\n\n\n\n<p>Licensor: Jiangsu Hengrui Pharmaceuticals(China)<\/p>\n\n\n\n<p>Capital:  BCLS Fund A, Atlas Ventures, RTW Fund, Lyra Capital<\/p>\n\n\n\n<p>NewCo Name:  Hercules CM NewCo, Inc. (established in 2024-05, USA; 2025-10-01, new company Kailera Therapeutics established\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset 1:     HRS9531 (KAI-9531)  (Injectable) <\/p>\n\n\n\n<p>Modality: Peptide.  Target: GLP-1\/GIP receptor dual agonist. <\/p>\n\n\n\n<p>Current Stage: Phase II, in China (Leading Asset)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset 2:   HRS-7535 (KAI-7535)<\/p>\n\n\n\n<p>Modality: Small Molecule.  Target: GLP-1 receptor agonist.  Oral tablet.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset 3:   HRS9531 (KAI-9531) (0ral)<\/p>\n\n\n\n<p>Modality: Peptide.  Target: GLP-1\/GIP receptor dual agonist. <\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset 4: HRS-4729 (KAI-4729)<\/p>\n\n\n\n<p>Modality: Peptide. Target: GLP-1\/GIP\/Glucagon Receptor Tri-Agonist. Injection.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority: &nbsp;<\/p>\n\n\n\n<p>Hengrui Pharmaceuticals granted the exclusive global rights to its drug portfolio&nbsp;to a newly established company under US private investment firm Bain Capital.<\/p>\n\n\n\n<p>Hercules CM Newco&nbsp;will obtain the development, production, and commercialization rights worldwide, excluding China, for Hengrui&#8217;s GLP-1 diabetes and weight-loss drug.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Hengrui will be eligible to receive:<\/p>\n\n\n\n<p> 19.9% stake in Kailera.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Upfront payment and near-term payment of $110 million,<\/p>\n\n\n\n<p>Development and regulatory milestone payments up to \u00a0$200 million (base on HRS9531)<\/p>\n\n\n\n<p>Sales milestone payments of up to $5.725 billion.<\/p>\n\n\n\n<p>Total up to $6.035 billion.<\/p>\n\n\n\n<p>Tiered royalties on net sales.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link: <a href=\"https:\/\/static.sse.com.cn\/disclosure\/listedinfo\/announcement\/c\/new\/2024-05-17\/600276_20240517_URE4.pdf\">600276_20240517_URE4.pdf (sse.com.cn)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-08-29 (May 29, 2024) Key Asset: Four GLP-1 Programs, HRS9531 (KAI-9531)\u3001HRS-7535 (KAI-7535)\u3001HRS-4729 (KAI-4729) Licensor: &hellip; <a title=\"[China NewCo 2024] Hengrui  and Hercules CM NewCo enters a license on 4 GLP-1 Programs\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/154.html\"><span class=\"screen-reader-text\">[China NewCo 2024] Hengrui  and Hercules CM NewCo enters a license on 4 GLP-1 Programs<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-154","post","type-post","status-publish","format-standard","hentry","category-newco"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=154"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/154\/revisions"}],"predecessor-version":[{"id":162,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/154\/revisions\/162"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}